Department of Pharmacology and Cancer Biology

Department of Pharmacology and Cancer Biology
Name	Department of Pharmacology and Cancer Biology
Established	1995
Parent	Duke University School of Medicine
City	Durham, North Carolina
Country	United States
Head label	Chair
Head	Christopher Counter
Website	https://pharmacology.mc.duke.edu/

Department of Pharmacology and Cancer Biology. It is a premier academic and research unit within the Duke University School of Medicine, located on the university's health system campus in Durham, North Carolina. The department is distinguished by its integrated mission to advance fundamental pharmacology and apply those discoveries to understand the mechanisms of cancer and develop novel therapeutics. Its faculty and trainees operate at the intersection of basic science and translational medicine, contributing significantly to the broader research enterprise of Duke University and the international scientific community.

History and establishment

The department was formally established in 1995 through the strategic merger of the former Department of Pharmacology with cancer biology research initiatives, a reorganization championed by the Duke University School of Medicine leadership to foster interdisciplinary science. This consolidation was part of a broader vision to create a powerful nexus for drug discovery and oncogenesis research, aligning with the growth of the Duke Cancer Institute. Key early figures in its foundation included prominent scientists and administrators who recognized the synergistic potential of combining molecular pharmacology with cutting-edge cancer research. Since its inception, the department has evolved into a nationally recognized center, consistently ranked among the top programs in its field by organizations like the National Institutes of Health.

Academic programs and research focus

The department administers a highly selective PhD program in Pharmacology and a specialized training track in Cancer Biology, attracting graduate students from top institutions worldwide. Its research focus is broadly organized around several interconnected themes: the signal transduction pathways driving tumorigenesis, the mechanisms of DNA repair and genomic instability, the pharmacokinetics and pharmacodynamics of anticancer agents, and the development of targeted therapy and immunotherapy. Collaborative research extends into neuropharmacology, chemical biology, and computational drug design, often involving close partnerships with the Duke Clinical Research Institute and the Duke Molecular Physiology Institute.

Faculty and key personnel

The department is led by Chair Christopher Counter, a renowned researcher in pancreatic cancer and RAS oncogene biology. The faculty comprises a mix of esteemed senior investigators and rising stars, including members of the National Academy of Sciences and recipients of prestigious awards like the Howard Hughes Medical Institute Investigator designation and the American Association for Cancer Research awards. Notable faculty have included experts in cell cycle regulation, chromatin biology, and developmental therapeutics. The department also benefits from adjunct and joint appointments with other units such as the Department of Biochemistry and the Department of Medicine, enhancing its interdisciplinary reach.

Research facilities and resources

Researchers have access to state-of-the-art core facilities within the Duke University School of Medicine and the broader Duke University Health System. These include advanced resources for high-throughput screening, mass spectrometry, flow cytometry, confocal microscopy, and genomic sequencing. The department's laboratories are primarily housed in modern research buildings on the Duke University Medical Center campus, including the Nanaline H. Duke building and the Jones research complex. These spaces are designed to facilitate collaboration and provide integrated environments for biochemical assay development, preclinical model studies, and translational research.

Notable discoveries and contributions

Department investigators have been pivotal in several landmark discoveries. These include seminal work elucidating the role of the RAS pathway in human cancers, pioneering studies on checkpoint kinase inhibitors, and fundamental advances in understanding cytotoxic chemotherapy resistance. Faculty research has directly contributed to the development of clinical-stage small molecule inhibitors and novel therapeutic strategies evaluated in trials through the Duke Cancer Institute. Their work is regularly published in high-impact journals such as Cell, Nature, and Science, and has influenced guidelines set by organizations like the National Comprehensive Cancer Network.

Affiliations and partnerships

The department maintains integral affiliations with major research centers at Duke, most notably the Duke Cancer Institute, an National Cancer Institute-designated comprehensive cancer center. It also has strong collaborative ties with the Duke Institute for Genome Sciences & Policy, the Duke Center for Applied Genomics and Precision Medicine, and various industry partners in the Research Triangle Park biopharmaceutical sector. These partnerships facilitate translational pipelines, support training grants from the National Institute of General Medical Sciences, and enable participation in large-scale consortia such as the Cancer Genome Atlas project.

Category:Duke University School of Medicine Category:Pharmacology departments in the United States Category:Cancer research organizations in the United States